

## REFERENCES ON PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING AND ITS APPLICATION IN RISK ASSESSMENT

### BOOKS

Modeling of Inhalation Exposure to Vapors: Uptake Distribution and Elimination. Volumes 1 and 2. V. Fiserova-Bergerova, ed. CRC Press, Boca Raton FL, 1983.

Pharmacokinetics in Risk Assessment. Drinking Water and Health. Volume 8. National Research Council. National Academy Press, Washington D.C., 1987.

Principles of Route-to-Route Extrapolation for Risk Assessment. T.R. Gerrity and C.J. Henry, eds. Elsevier, New York N.Y., 1990.

Report of the Task Group on Reference Man. International Commission on Radiological Protection, ICRP Publication 23, 1975.

Textbook of Work Physiology. Astrand, P., and Rodahl, K., ed. McGraw-Hill, New York, 1970.

### PUBLICATIONS

Albertini, R., Clewell, H., Himmelstein, M.W., Morinello, E., Olin, S., Preston, J., Scarano, L., Smith, M.T., Swenberg, J., Tice, R., Travis, C., 2003. The use of non-tumor data in cancer risk assessment: reflections on butadiene, vinyl chloride, and benzene. *Regul. Toxicol. Pharmacol.* 37 (1), 105–132.

Allen, B.C., and Fisher, J. 1993. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. *Risk Anal* 13:71-86.

Allen, B.C., Covington, T.R., and Clewell, H.J. 1996. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. *Toxicology* 111:289-303.

Andersen, M.E. 1981. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. *Toxicol Appl Pharmacol* 60:509-26.

Andersen, M.E. 1981. Saturable metabolism and its relation to toxicity. *Crit Rev Toxicol* 9, 105–150.

Andersen, M.E. 1995. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. *Toxicol Lett* 79:35-44.

Andersen, M.E., Clewell, H.J., and Frederick, C.B. 1995. Applying simulation modeling to problems in toxicology and risk assessment C a short perspective. *Toxicol Appl Pharmacol* 133:181-187.

Andersen, M.E., Clewell, H.J., Gargas, M.L., Smith, F.A. and Reitz, R.H. 1987. Physiologically-based pharmacokinetics and the risk assessment for methylene chloride. *Toxicol Appl Pharmacol* 87:185-205.

Andersen, M.E., Clewell, H.J., III, Gargas, M.L., MacNaughton, M.G., Reitz, R.H., Nolan, R., and McKenna, M. 1991. Physiologically based pharmacokinetic modeling with dichloromethane, its

metabolite carbon monoxide, and blood carboxyhemoglobin in rats and humans. *Toxicol Appl Pharmacol* 108:14-27.

Andersen, M.E., Clewell, III, H.J., Gearhart, J.G., Allen, B.C., and Barton, H.A.. 1997. Pharmacodynamic model of the rat estrus cycle in relation to endocrine disruptors. *J Toxicol Environ Health* 52:189-209.

Andersen, M.E., Clewell, H.J., and Krishnan, K. 1995. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. *Risk Anal* 15:533-537.

Andersen, M.E., Clewell, H.J., Mahle, D.A., and Gearhart, J.M. 1994. Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. *Toxicol Appl Pharmacol* 128:158-165.

Andersen, M.E., Ecklund, C.R., Mills, J.J., Barton, H.A., and Birnbaum, L.S. 1997. A multi-compartment geometric model of the liver acinus in relation to regional induction of cytochrome P450s by transcriptional mechanisms. *Toxicol Appl Pharmacol* (in press).

Andersen, M.E., Gargas, M.L., Clewell, H.J., and Severyn, K.M. 1987. Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene by gas uptake methods. *Toxicol Appl Pharmacol* 89:149-157.

Andersen, M.E., Gargas, M.L., Hays, S.M., Clewell, H.J., III, and Paustenbach, D.J. 1997. Estimating minimally effective inducing doses (ED01s) of TCDD in livers of rats and humans using physiologically based pharmacokinetic modeling. *Organohalogen Compounds* 34:311-316.

Andersen, M.E., Gargas, M.L., and Ramsey, J.C. 1984. Inhalation pharmacokinetics: Evaluating systemic extraction, total in vivo metabolism and the time course of enzyme induction for inhaled styrene in rats based on arterial blood: inhaled air concentration ratios. *Toxicol Appl Pharmacol* 73:176-187.

Andersen, M.E., Krewski, D., and Withey, J.R. 1993. Physiological pharmacokinetics and cancer risk assessment. *Cancer Lett* 69:1-14.

Andersen, M.E., and Krishnan, K. 1994. Physiologically based pharmacokinetics and cancer risk assessment. *Environ Health Perspect* 1:103-8.

Andersen, M.E., MacNaughton, M.G., Clewell, H.J., and Paustenbach, D.J. 1987. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. *Am Ind Hyg Assoc J* 48:335-343.

Andersen, M.E., Mills, J.J., Gargas, M.L., Kedderis, L., Birnbaum, L.S., Norbert, D., and Greenlee, W.F. 1993. Modeling receptor-mediated processes with dioxin: Implications for pharmacokinetics and risk assessment. *Risk Anal* 13:25-36.

Andersen, M.E., Sarangapani R., Gentry P.R., Clewell, H.J., Covington, T.R., and Frederick, C.B. 2000. Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid. *Toxicol. Sci.* 57:312-325.

Ball, R., and Schwartz, S.L. 1994. CMATRIX: software for physiologically based pharmacokinetic modeling using a symbolic matrix representation system. *Comput Biol Med* 24:269-276.

- Barton, H.A., Andersen, M.E., and Clewell, H.J., III 1998. Harmonization: Developing consistent guidelines for applying model of action and dosimetry information to cancer and noncancer risk assessment. *Human Ecological Risk Assessment* 4(1):75-115.
- Barton, H.A., Clewell, H.J., 2000. Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment. *Environ. Health Perspect.* 108 (Suppl. 2), 323–334.
- Barton, H.A., Creech, J.R., Godin, C.S., Randall, G.M., and Seckel, C.S. 1995. Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. *Toxicol Appl Pharmacol* 130:237-247.
- Beck, B.D., and Clewell, H.J. 2001. Uncertainty/Safety Factors in Health Risk Assessment: Opportunities for Improvement. *Human and Ecological Risk Assessment* 7(1):203 207.
- Beck, B.D., Conolly, R.B., Dourson, M.L., Guth, D., Hattis, D., Kimmel, C., and Lewis, S.C. 1993. Improvements in quantitative noncancer risk assessment. Sponsored by the Risk Assessment Specialty Section of the Society of Toxicology. *Fundam Appl Toxicol* 20:1-14.
- Becking, G.C. 1995. Use of mechanistic information in risk assessment for toxic chemicals. *Toxicol Lett* 77:15-24.
- Bischoff, K.B., and Brown, R.G. 1966. Drug distribution in mammals. *Chem Eng Prog Symp Ser* 62(66):33-45.
- Bischoff, K.B., Dedrick, R.L., Zaharko, D.S., and Longstreth, J.A. 1971. Methotrexate pharmacokinetics. *J Pharm Sci* 60:1128-1133.
- Bogdanffy, M.S., Daston, G., Faustman, E.M., Kimmel, C.A., Kimmel, G.L., Seed, J., Vu, V., 2001a. Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop. *Toxicol. Sci.* 61 (1), 18–31.
- Bogen, K.T. 1988. Pharmacokinetics for regulatory risk analysis: the case of trichloroethylene. *Regul Toxicol Pharmacol* 8:447-466.
- Bogen K.T., and Hall, L.C. 1989. Pharmacokinetics for regulatory risk analysis: the case of 1,1,1-trichloroethane (methyl chloroform). *Regul Toxicol Pharmacol* 10:26-50.
- Bogen, K.T., and McKone, T.E. 1988. Linking indoor air and pharmacokinetic models to assess tetrachloroethylene risk. *Risk Anal* 8:509-520.
- Bois, F.Y., Zeise, L., and Tozer, T. N. 1990. Precision and Sensitivity of Pharmacokinetic Models for Cancer Risk Assessment: Tetrachloroethylene in Mice, Rats, and Humans. *Toxicol Appl Pharmacol* 102:300-315.
- Bolt, H.M. 1996. Butadiene and isoprene: future studies and implications. *Toxicology* 113:356-360.
- Bookout, R.L., Jr, McDaniel, C.R., Quinn, D.W., and McDougal, J.N. 1996. Multilayered dermal subcompartments for modeling chemical absorption. *Environ Res* 5:133-150.

- Borghoff, S.J., Gargas, M.L., Andersen, M.E., and Conolly, R.B. 1995. Development of a mechanism-based dosimetry model for 2,4,4-trimethyl-2-pentanol-induced alpha 2u-globulin nephropathy in male Fischer 344 rats. *Fundam Appl Toxicol* 25:124-137.
- Borghoff, S.J., Murphy, J.E., and Medinsky, M.A. 1996. Development of physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fisher-344 rats. *Fundam Appl Toxicol* 30:264-275.
- Brodeur, J., Lapare, S., Krishnan, K., Tardif, R., and Goyal, R. 1990. The problem of adjusting threshold limit values (TLVs) for non-conventional work schedules: utility of physiologically-based pharmacokinetic modeling. *Travail et Sante Summer* 6:S.
- Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., and Beliles, R.P. 1997. Physiological parameter values for physiologically based pharmacokinetic models. *Toxicol Indust Health* 13(4):407-484.
- Buckley, L.A. 1995. Biologically-based models of dioxin pharmacokinetics. *Toxicology* 102:125-131.
- Bungay, P.M., R.L. Dedrick, and H.B. Matthews. 1981. Enteric transport of chlordecone (Kepone ) in the rat. *J Pharmacokinet Biopharm* 9:309-341.
- Byczkowski, J.Z., and Fisher, J.W. 1994. Lactational transfer of tetrachloroethylene in rats. *Risk Anal* 14:339-349.
- Byczkowski, J.Z., and Fisher, J.W. 1995. A computer program linking physiologically based pharmacokinetic model with cancer risk assessment for breast-fed infants. *Comput Meth Prog Biomed* 46:155-163.
- Byczkowski, J.Z., Kinkead, E.R., Leahy, H.F., Randall, G.M., and Fisher, J.W. 1994. Computer simulation of the lactational transfer of tetrachloroethylene in rats using a physiologically based model. *Toxicol Appl Pharmacol* 125:228-236.
- Cantoreggi, S., and Keller, D.A. 1997. Pharmacokinetics and metabolism of vinyl fluoride in vivo and in vitro. *Toxicol Appl Pharmacol* 143:130-139.
- Casanova, M., Conolly, R.B., and Heck, H. 1996. DNA-protein cross-links (DPX) and cell proliferation in B6C3F1 mice but not Syrian golden hamsters exposed to dichloromethane: pharmacokinetics and risk assessment with DPX as dosimeter. *Fundam Appl Toxicol* 31:103-116.
- Charnick, S.B., Kawai, R., Nedelman, J.R., Lemaire, M., Niederberger, W., and Sato, H. 1995. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development [see comments]. *J Pharmacokinet Biopharm* 23:217-229.
- Chen, C.W., and Blancato, J.N. 1989. Incorporation of biological information in cancer risk assessment: example - vinyl chloride. *Cell Biol Toxicol* 5:417-444.
- Clark, L.H., Setzer, R.W., Barton, H.A., 2004. Framework for evaluation of physiologically based pharmacokinetic models for use in safety or risk assessment. *Risk Anal.* 24, 1697–1718.

Clarke, D.O., Elswick, B.A., Welsch, F., and Conolly, R.B. 1993. Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model. *Toxicol Appl Pharmacol* 121:239-252.

Clarke, D.O., Welsch, F., and Conolly, R.B. 1991. Development of a physiologically-based description of 2-methoxyethanol (2-ME) pharmacokinetics in the pregnant mouse. *Teratology* 43:437.

Clewell, H.J. 1993. Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. *Toxicol Lett* 68:101-117.

Clewell, H.J. 1995. Incorporating biological information in quantitative risk assessment: an example with methylene chloride. *Toxicology* 102:83-94.

Clewell, H.J. 1995. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. *Toxicol Lett* 79:207-217.

Clewell, H.J. 1995. The use of physiologically based pharmacokinetic modeling in risk assessment: a case study with methylene chloride. In: *Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives*. Olin, S., Farland, W., Park, C., Rhomberg, L., Scheuplein, R., Starr, T., and Wilson, J., eds. ILSI Press, Washington, D.C.

Clewell, H.J. 2005. Use of mode of action in risk assessment: past, present, and future. *Reg Tox Pharm*, 42:3-14.

Clewell, H.J., and Andersen, M.E. 1985. Risk Assessment Extrapolations and Physiological Modeling. *Toxicol Ind Health*, 1(4):111-131.

Clewell, H.J., and Andersen, M.E. 1989. Biologically Motivated Models for Chemical Risk Assessment. *Health Phys* 57(Suppl 1):129-137.

Clewell, H.J., and Andersen, M.E. 1996. Use of physiologically-based pharmacokinetic modeling to investigate individual versus population risk. *Toxicology* 111:315-329.

Clewell, H.J., Andersen, M.E., 2004. Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. *Crit. Rev. Toxicol.* 34 (5), 385-445.

Clewell, H.J., Andersen, M.E., Barton, H.A., 2002. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. *Environ. Health Perspect.* 110, 85-93.

Clewell, H.J., Andersen, M.E., Wills, R.J., and Latriano, L. 1997. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. *J Am Acad Dermatol* 36:S77-85.

Clewell, H.J., and Crump, K.S. 2005. Quantitative Estimates of Risk for Non-Cancer Endpoints. *Risk Anal.* 25(2):285-289.

Clewell RA, Gearhart JM. 2002. Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. *Environ Health Perspect.* 110(6):A333-7.

Clewell, H.J., Gearhart, J.M., Gentry, P.R., Covington, T.R., VanLandingham, C.B., Crump, K.S., and

Shipp, A.M. 1999. Evaluation of the uncertainty in an oral Reference Dose for methylmercury due to interindividual variability in pharmacokinetics. *Risk Anal* 19:547-558.

Clewell HJ, Gentry PR, Allen BC, Covington TR, and Gearhart JM. 2000. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. *Environmental Health Perspectives*, 108(suppl 2):283-305.

Clewell, H.J., Gentry, P.R., Covington, T.R., Sarangapani, R., and Teeguarden, J.G. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. *Toxicol. Sci.* 79:381-393.

Clewell, H.J. III, Gentry, P.R., Gearhart, J.M. 1997. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. *J Toxicol Environ Health* 52:475-515.

Clewell, H.J., Gentry, P.R., Gearhart, J.M., Allen, B.C., and Andersen, M.E. 1995. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. *Chemosphere* 31:2561-2578.

Clewell, H.J., Gentry, P.R., Gearhart, J.M., Allen, B.C., Andersen, M.E., 2001. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. *Sci. Total Environ.* 274 (1-3), 37-66.

Clewell, H.J., Gentry, P.R., Gearhart, J.M., Covington, T.R., Banton, M.I., and Andersen, M.E. 2001. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. *Toxicol. Sci.* 63:160-172.

Clewell, H.J., Gentry, P.R., Kester, J.E., and Andersen, M.E. 2005. Evaluation of physiologically based pharmacokinetic models in risk assessment: An example with perchloroethylene. *Crit Rev Toxicol*, 35:413-433.

Clewell, H.J., and Jarnot, B.M. 1994. Incorporation of pharmacokinetics in non-carcinogenic risk assessment: Example with chloropentafluorobenzene. *Risk Anal* 14:265-276.

Clewell, H.J., Lee, T., and Carpenter, R.L. 1994. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. *Risk Anal* 14:521-531.

Clewell RA, Merrill EA, Robinson PJ. 2001. The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species. *Toxicol Ind Health.* 17(5-10):210-22.

Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Fisher JW, Gearhart JM. 2003. Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. *Toxicol Sci.* 74(2):416-36.

Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Mattie DR, Robinson PJ, Fisher JW, Gearhart JM. 2003. Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. *Toxicol Sci.* 73(2):235-55.

Clewell, H.J., Teeguarden, J., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry, P.R., and Shipp, A.M. 2002. Review and Evaluation of the Potential Impact of Age and Gender-Specific

Pharmacokinetic Differences on Tissue Dosimetry. *Crit Rev Toxicol* 32(5):329-389.

Clewell, H.J., Quinn, D., Andersen, M.E., and Conolly, R.B. 1995. A straightforward approximation to the exact solution of the two stage clonal growth model of cancer. *Risk Anal* 15:467-473.

Conolly, R.B., Morgan, K.T., Andersen, M.E., Monticello, T.M., and Clewell, H.J. 1992. A biologically-based risk assessment strategy for inhaled formaldehyde. *Comm Toxicol* 4:269-293.

Conolly, R.B., Reitz, R.H., Clewell, H.J., and Andersen, M.E. 1988. Biologically structured models and computer simulation. *Comm Toxicol* 2:305-319.

Conolly, R.B., Reitz, R.H., Clewell, H.J., and Andersen, M.E. 1988. Pharmacokinetics, biochemical mechanism and mutation accumulation: A comprehensive model of chemical carcinogenesis. *Toxicol Lett* 43:189-200.

Corley, R.A., Bormett, G.A., Ghanayem, B.I., 1994. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. *Toxicol. Appl. Pharmacol.* 129, 61-79.

Corley, R.A., Markham, D.A., Banks, C., Delorme, P., Masterman, A., Houle, J.M., 1997. Physiologically-based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapors by humans. *Toxicol. Appl. Pharmacol.* 39, 120-130.

Corley, R.A., Mendrala, A.L., Smith, F.A., Staats, D.A., Gargas, M.L., Conolly, R.B., Andersen, M.E., and Reitz, R.H. 1990. Development of a physiologically based pharmacokinetic model for chloroform. *Toxicol Appl Pharmacol* 103:512-527.

Cox, L.A., Jr. 1995. Simple relations between administered and internal doses in compartmental flow models. *Risk Anal* 15:197-204.

Cox, L.A., Jr. 1996. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. *Environ Health Perspect* 104(Suppl 6):1413-1429.

Crank, W.D., and Vinegar, A. 1992. A physiologically based pharmacokinetic model for chloropentafluorobenzene in primates to be used in the evaluation of protective equipment against toxic gases. *Toxicol Ind Health.* 8(1/2):21-35.

Cronin, W.J., Oswald, E.J., Shelley, M.L., Fisher, J.W., and Flemming, C.D. 1995. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling. *Risk Anal* 15:555-565.

Crump K., 1984. An improved procedure for low-dose carcinogenic risk assessment from animal data. *J Environ Pathol Toxicol* 5, 339-348.

Crump, K.S., 1995. Calculation of benchmark doses from continuous data. *Risk Anal* 15, 79-89.

Crump, K.S., Clewell, H.J., III, and Andersen, M.E. 1997. Cancer and Non-Cancer Risk Assessments Should be Harmonized. *Human Ecol Risk Assess* 3:495-499.

Csanady, G.A., Mendrala, A.L., Nolan, R.J., and Filser, J.G. 1994. A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man. *Arch Toxicol* 68:143-157.

- Dallas, C.E., Chen, X.M., Muralidhara, S, Varkonyi, P., Tackett, R.L., and Bruckner, J.V. 1994. Use of tissue disposition data from rats and dogs to determine species differences in input parameters for a physiological model for perchloroethylene. *Environ Res* 67:54-67.
- Dallas, C.E., Chen, X.M., Muralidhara, S, Varkonyi, P., Tackett, R.L., and Bruckner, J.V. 1995. Physiologically based pharmacokinetic model useful in prediction of the influence of species, dose, and exposure route on perchloroethylene pharmacokinetics. *J Toxicol Environ Health* 44:301-317.
- Dallas, C.E., Chen, X.M., O'Barr, K., Muralidhara, S., Varkonyi, P., and Bruckner, J.V. 1994. Development of a physiologically based pharmacokinetic model for perchloroethylene using tissue concentration-time data. *Toxicol Appl Pharmacol* 128:50-59.
- Dallas, C.E., Muralidhara, S., Chen, X.M., Ramanathan, R., Varkonyi, P., Gallo, J.M., and Bruckner, J.V. 1994. Use of a physiologically based model to predict systemic uptake and respiratory elimination of perchloroethylene. *Toxicol Appl Pharmacol* 128:60-68.
- Dankovic, D., and Bailer, A.J. 1993. The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model. *Fundam Appl Toxicol* 22:20-25.
- Davies, B., and Morris, T. 1993. Physiological parameters in laboratory animals and humans. *Pharmaceut Res* 10:1093-1095.
- Dedrick, R.L. 1973. Animal scale-up. *J Pharmacokinet Biopharm* 1:435-461.
- Dedrick, R.L., and Bischoff, K.B. 1980. Species similarities in pharmacokinetics. *Fed Proc* 39:54-59.
- Dong, M.H. 1994. Microcomputer programs for physiologically-based pharmacokinetic (PB-PK) modeling. *Comput Meth Prog Biomed* 45:213-221.
- Dourson, M.L., Felter, S.P., Robinson, D., 1996. Evolution of science based uncertainty factors in noncancer risk assessment. *Reg. Tox. Pharmacol.* 24, 108–120.
- Dourson, M.L., Stara, J., 1983. Regulatory history and experimental support of uncertainty (safety) factors. *Reg. Tox. Pharmacol.* 3, 224–238.
- Droz, P.O., Wu, M.M., and Cumberland, W.G. 1989. Variability in biological monitoring of solvent exposure. II. Application of a population physiological model. *Br J Ind Med* 46:547-558.
- Droz, P.O., Wu, M.M., Cumberland, W.G., and Berode, M. 1989. Variability in biological monitoring of solvent exposure. I. Development of a population physiological model. *Br J Ind Med* 46:447-460.
- D'Souza, R.W., and Andersen, M.E. 1988. Physiologically based pharmacokinetic model for vinylidene chloride. *Toxicol Appl Pharmacol* 95:230-240.
- D'Souza, R.W., and Boxenbaum, H. 1988. Physiological pharmacokinetic models: Some aspects of theory, practice and potential. *Toxicol Ind Health* 4(2):151-171.
- D'Souza, R.W., Francis, W.R., and Andersen, M.E. 1988. Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. *J Pharmacol Exp Ther* 245:563-568.

- Ebling, W.F., Wada, D.R., and Stanski, D.R. 1994. From piecewise to full physiologic pharmacokinetic modeling: applied to thiopental disposition in the rat. *J Pharmacokinet Biopharm* 22:259-292.
- el-Masri, H.A., Constan, A.A., Ramsdell, H.S., and Yang, R.S. 1996. Physiologically based pharmacodynamic modeling of an interaction threshold between trichloroethylene and 1,1-dichloroethylene in Fischer 344 rats. *Toxicol Appl Pharmacol* 141:124-132.
- el-Masri, H.A., Tessari, J.D., and Yang, R.S. 1996. Exploration of an interaction threshold for the joint toxicity of trichloroethylene and 1,1-dichloroethylene: utilization of a PBPK model. *Arch Toxicol* 70:527-339.
- el-Masri, H.A., Thomas, R.S., Benjamin, S.A., and Yang, R.S. 1995. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. *Toxicology* 105:275-282.
- el-Masri, H.A., Thomas, R.S., Sabados, G.R., Phillips, J.K., Constan, A.A., Benjamin, S.A., Andersen, M.E., Mehendale, H.H., and Yang, R.S. 1996. Physiologically based pharmacokinetic/pharmacodynamic modeling of the toxicologic interaction between carbon tetrachloride and kepone. *Arch Toxicol* 70:704-713.
- Evans, M.V., and Simmons, J.E. 1996. Physiologically based pharmacokinetic estimated metabolic constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. *Toxicol Appl Pharmacol* 140:245-253.
- Evans, M.V., Crank, W.D., Yang, H.M., and Simmons, J.E. 1994. Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. *Toxicol Appl Pharmacol* 128:36-44.
- Farrar, D., Allen, B., Crump, K., and Shipp, A. 1989. Evaluation of Uncertainty in Input Parameters to Pharmacokinetic Models and the Resulting Uncertainties in Output. *Toxicol Lett* 49:371-385.
- Farris, F.F., Dedrick, R.L., Allen, P.V., and Smith, J.C. 1993. Physiological model for the pharmacokinetics of methyl mercury in the growing rat. *Toxicol Appl Pharmacol* 119:74-90.
- Farris, F.F., Dedrick, R.L., and King, F.G. 1988. Cisplatin pharmacokinetics: Application of a physiological model. *Toxicol Lett* 43:117-137.
- Filser, J.G., Csanady, G.A., Kreuzer, P.E., and Kessler, W. 1995. Toxicokinetic models for volatile industrial chemicals and reactive metabolites. *Toxicol Lett* 82-83:357-366.
- Filser, J.H., Johanson, G., Kessler, W., Kreuzer, P.E., Stei, P., Baur, C., and Csanady, G.A. 1993. A pharmacokinetic model to describe toxicokinetic interactions between 1,3-butadiene and styrene in rats: predictions for human exposure. *IARC Sci Publ* 127:65-78.
- Fiserova-Bergerova V, 1975. Biological – Mathematical Modeling of Chronic Toxicity. AMRL-TR-75-5. Wright- Patterson Air Force Base, OH:Aerospace Medical Research Laboratory.
- Fiserova-Bergerova, V., Vlach, J., and Cassady, J.L. 1980. Predictable "individual differences" in uptake and excretion of gases and lipid soluble vapours: simulation study. *Br J Ind Med* 37:42-49.

- Fisher J.W., and Allen, B.C. 1993. Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. *Risk Anal* 13:87-95.
- Fisher, J., Gargas, M., Allen, B., and Andersen, M. 1991. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. *Toxicol Appl Pharmacol* 109:183-195.
- Fisher, J.W., Whittaker, T.A., Taylor, D.H., Clewell, H.J., and Andersen, M.E. 1990. Physiologically-based pharmacokinetic modeling of the lactating rat and nursing pup: A multi-route exposure model for trichloroethylene and its metabolite, trichloroacetic acid. *Toxicol Appl Pharmacol* 102:497-513.
- Fisher, J.W., Whittaker, T.A., Taylor, D.H., Clewell, H.J., III, and Andersen, M.E. 1989. Physiologically based pharmacokinetic modeling of the pregnant rat: A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. *Toxicol Appl Pharmacol* 99:395-414.
- Frederick, C.B. 1993. Limiting the uncertainty in risk assessment by the development of physiologically based pharmacokinetic and pharmacodynamic models. *Toxicol Lett* 68:159-175.
- Frederick, C.B., Potter, D.W., Chang-Mateu, M.I., and Andersen, M.E. 1992. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. *Toxicol Appl Pharmacol* 114:246-260.
- Freeman, R.A., Rozman, K.K., and Wilson, A.G.E. 1989. Physiological pharmacokinetic model for hexachlorobenzene in the rat. *Health Phys* 57(Suppl 1):139-147.
- Gallo, J.M., Cheung, L.L., Kim, H.J., Bruckner, J.V., and Gillespie, W.R. 1993. A physiological and system analysis hybrid pharmacokinetic model to characterize carbon tetrachloride blood concentrations following administration in different dosing vehicles. *J Pharmacokinet Biopharm* 21:551-574.
- Gargas, M.L. 1990. An exhaled breath chamber system for assessing rates of metabolism and rates of gastrointestinal absorption with volatile compounds. *J Am Coll Toxicol* 9:447-453.
- Gargas, M.L., and Andersen, M.E. 1982. Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. *Toxicol Appl Pharmacol* 66:55-68.
- Gargas, M.L., and Andersen, M.E. 1989. Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. *Toxicol Appl Pharmacol* 99:344-353.
- Gargas, M.L., Andersen, M.E., and Clewell, H.J. 1986. A physiologically-based simulation approach for determining metabolic constants from gas uptake data. *Toxicol Appl Pharmacol* 86:341-352.
- Gargas, M.L., Andersen, M.E., Teo, S.K.O., Batra, R., Fennell, T.R., and Kedderis, G.L. 1995. A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. *Toxicol Appl Pharmacol* 134:185-194.
- Gargas, M.L., Burgess, R.J., Voisard, D.E., Cason, G.H., and Andersen, M.E. 1989. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. *Toxicol Appl Pharmacol* 98:87-99.

- Gargas, M.L., Clewell, H.J., and Andersen, M.E. 1986. Metabolism of inhaled dihalomethanes in vivo: Differentiation of kinetic constants for two independent pathways. *Toxicol Appl Pharmacol* 82:211-223.
- Gargas, M.L., Clewell, H.J., and Andersen, M.E. 1990. Gas uptake techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. *Inhal Toxicol* 2:295-319.
- Gargas, M.L., Medinsky, M.A., and Andersen, M.E. 1995. Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. *Crit Rev Toxicol* 25:237-254.
- Gearhart, J.M., Clewell, H.J., Crump, K.S., Shipp, A.M., and Silvers, A. 1995. Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study. *Water Air Soil Pollut* 80:49-58.
- Gearhart, J.M., Jepson, G.W., Clewell, H.J., Andersen, M.E., and Connolly, R.B. 1995. A physiologically-based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. *Environ Health Perspect* 102(11):51-60.
- Gearhart, J.M., Jepson, G.W., Clewell, H.J., Andersen, M.E., and Conolly, R.B. 1990. Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. *Toxicol Appl Pharmacol* 106:295-310.
- Gearhart, J.M., Seckel, C.S., and Vinegar, A. 1993. In vivo metabolism of chloroform in B6C3F1 mice determined by the method of gas uptake: the effects of body temperature on tissue partition coefficients and metabolism. *Toxicol Appl Pharmacol* 119:258-266.
- Gentry, P.R., Covington, T.R., Andersen, M.E. and Clewell, H.J. 2003. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone. *J Toxicol Environ Health (Part A)* 66:2209-2225.
- Gentry, P.R., Covington, T.R., and Clewell, H.J. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. *Reg Toxicol Pharmacol* 38(1):1-16.
- Gentry, P.R., Covington, T.R., Andersen, M.E., Clewell, H.J., 2002. Application of a physiologically-based pharmacokinetic model for isopropanol in the derivation of an RfD/RfC. *Reg. Toxicol. Pharmacol.* 36, 51-68.
- Gentry, P.R., Hack, C.E., Haber, L., Maier, A., and Clewell, III, H.J. 2002. An Approach for the Quantitative Consideration of Genetic Polymorphism Data in Chemical Risk Assessment: Examples with Warfarin and Parathion. *Toxicological Sciences* 70:120-139.
- Gerlowski, L.E., and Jain, R.K. 1983. Physiologically based pharmacokinetic modeling: Principles and applications. *J Pharm Sci* 72:1103-1126.
- Gerrity, T.R., Henry, C.J., eds., 1990. Principles of Route-to-Route Extrapolation for Risk Assessment. New York:Elsevier.
- Gray D.G. 1995. A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus. *Toxicol Appl Pharmacol* 132:91-102.

- Haber, F., 1924. Zur geschichte des gaskrieges. In: *Fünf Vortrage aus den Jahren 1920-1923*. Berlin:Springer, 76–92.
- Haber, L.T., Maier, A., Gentry, P.R., Clewell, H.J., and Dourson, M.L. 2002. Genetic Polymorphisms in Assessing Interindividual Variability in Delivered Dose. *Reg Tox Pharm* 35:177-197.
- Haber, L.T., Maier, A., Zhao, Q., Dollarhide, J.S., Savage, R.E., Dourson, M.L., 2001. Applications of mechanistic data in risk assessment: the past, present, and future. *Toxicol. Sci.* 61, 32–39.
- Haddad, S., Pelekis, M., and Krishnan, K. 1996. A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. *Toxicol Lett* 85:113-126.
- Hattis, D., Erdreich, L., Ballew, M., 1987. Human variability in susceptibility to toxic chemicals—a preliminary analysis of pharmacokinetic data from normal volunteers. *Risk Anal.* 7 (4), 415–426.
- Hattis, D., White, P., Marmorstein, L., and Koch, P. 1990. Uncertainties in pharmacokinetic modeling for perchloroethylene. I. Comparison of model structure, parameters, and predictions for low-dose metabolism rates for models derived by different authors. *Risk Anal* 10:449-458.
- Himmelstein, K.J., and Lutz, R.J. 1979. A review of the application of physiologically based pharmacokinetic modeling. *J Pharmacokinet Biopharm* 7:127-145.
- Hoang, K. 1995. Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. *Toxicol Lett* 79:99-106.
- Hoogenveen, R.T., Clewell, H.J.,III, Andersen, M.E., and Slob, W. 1999. An alternative exact solution of the two-stage clonal growth model of cancer. *Risk Anal* 19(1):9-14.
- International Programme on Chemical Safety (IPCS), 2001. *Guidance Document for the use of Data in Development of Chemical-Specific Adjustment Factors (CSAF) for Interspecies Differences and Human Variability in Dose/Concentration Response Assessment*. WHO/PCS/01.4. World Health Organization, Geneva.
- Islam, M.S., Zhao, L., Zhou, J., Dong, L., McDougal, J.N., and Flynn, G.L. 1996. Systemic uptake and clearance of chloroform by hairless rats following dermal exposure. I. Brief exposure to aqueous solutions. *Risk Anal* 16:349-357.
- Jarabek, A.M., 1995. Consideration of temporal toxicity challenges current default assumptions. *Inhal Toxicol* 7, 927–946.
- Jarabek, A.M., Fisher, J.W., Rubenstein, R., Lipscomb, J.C., Williams, R.J., Vinegar, A., and McDougal, J.N. 1994. Mechanistic insights aid the search for CFC substitutes: risk assessment of HCFC-123 as an example. *Risk Anal* 14:231-250.
- Jepson, G.W., Hoover, D.K., Black, R.K., McCafferty, J.D., Mahle, D.A., and Gearhart, J.M. 1994. A partition coefficient determination method for nonvolatile chemicals in biological tissues. *Fund Appl Toxicol* 22:519-524.
- Johanson, G. 1986, Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. *Toxicol Lett* 34:23-31.

- Johanson, G. 1991. Modelling of respiratory exchange of polar solvents. *Ann Occup Hyg* 35:323-329.
- Johanson, G., and Filser, J.G. 1993. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. *Arch Toxicol* 67:151-163.
- Johanson, G., and Filser, J.G. 1996. PBPK model for butadiene metabolism to epoxides: quantitative species differences in metabolism. *Toxicology* 113:40-47.
- Kamrin, M.A., Fischer, L.J., Suk, W.A., Fouts, J.R., Pellizzari, E., and Thornton, K. 1994. Assessment of human exposure to chemicals from Superfund sites. *Environ Health Perspect* 1:221-228.
- Kawai, R., Lemaire, M., Steimer, J.L., Bruelisauer, A., Niederberger, W., and Rowland, M. 1994. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. *J Pharmacokinet Biopharm* 22:327-365.
- Kedderis, G.L., Carfagna, M.A., Held, S.D., Batra, R., Murphy, J.E., and Gargas, M.L. 1993. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. *Toxicol Appl Pharmacol* 123:274-282.
- Kedderis, L.B., Mills, J.J., Andersen, M.E., and Birnbaum, L.S. 1993. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction. *Toxicol Appl Pharmacol* 121:87-98.
- Kenyon, E.M., Kraichely, R.E., Hudson, K.T., and Medinsky, M.A. 1996. Differences in rates of benzene metabolism correlate with observed genotoxicity. *Toxicol Appl Pharmacol* 136:49-56.
- Kester, J.E., and Clewell, H.J. 2004. The perils and promise of modern risk assessment: the example of trichloroethylene. *Clin Occup Environ Med*, 4:497-512.
- Kim, C.S., Binienda, Z., and Sandberg, J.A. 1996. Construction of a physiologically based pharmacokinetic model for 2,4-dichlorophenoxyacetic acid dosimetry in the developing rabbit brain. *Toxicol Appl Pharmacol* 136:250-259.
- Kim, C.S., Gargas, M.L., and Andersen, M.E. 1994. Pharmacokinetic modeling of 2,4-dichlorophenoxyacetic acid (2,4-D) in rat and in rabbit brain following single dose administration. *Toxicol Lett* 74:189-201.
- Kim, C.S., Slikker, Jr., W., Binienda, Z., Gargas, M.L., and Andersen, M.E. 1995. Development of a physiologically based pharmacokinetic model for 2,4-dichlorophenoxyacetic acid dosimetry in discrete areas of the rabbit brain. *Neurotoxicol Teratol* 17:111-120.
- King, F.G., Dedrick, R.L., Collins, J.M., Matthews, H.B., and Birnbaum, L.S. 1983. Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. *Toxicol Appl Pharmacol* 67:390-400.
- Koizumi A. 1989. Potential of physiologically based pharmacokinetics to amalgamate kinetic data of trichloroethylene and tetrachloroethylene obtained in rats and man. *Br J Ind Med* 46:239-249.
- Krewski, D., Wang, Y., Bartlett, S., and Krishnan, K. 1995. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. *J Biopharm Stat* 5:245-271.

- Krewski, D., Withey, J.R., Ku, L.F., and Andersen, M.E. 1994. Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment. *Environ Health Perspect* 11:37-50.
- Kriebel, D. 1994. The dosimetric model in occupational and environmental epidemiology. *Occup Hyg* 1:55-68.
- Krishnan, K., Clewell, H.J., and Andersen, M.E. 1994. Physiologically based pharmacokinetic analyses of simple mixtures. *Environ Health Perspect* 102(Suppl 9):151-155.
- Krishnan, K., Gargas, M.L., Fennell, T.R., and Andersen, M.E. 1992. A physiologically based description of ethylene oxide dosimetry in the rat. *Toxicol Ind Health* 8(3):121-140.
- Krishnan, K., Haddad, S., and Pelekis, M. 1995. A simple index for representing the discrepancy between simulations of physiological pharmacokinetic models and experimental data. *Toxicol Ind Health* 11:413-422.
- Lam, G., Chen, M. and Chiou, W.L. 1981. Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. *J Pharm Sci* 71(4):454-456.
- Leavens, T.L., and Bond, J.A. 1996. Pharmacokinetic model describing the disposition of butadiene and styrene in mice. *Toxicology* 113:310-313.
- Lehman, A.J., Fitzhugh, O.G., 1954. 100-fold margin of safety. *Assoc. Food Drug OV. U.S. Q. Bull.* 18, 33-35.
- Leung, H.W. 1991. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. *J Toxicol Environ Health* 32:247-267.
- Leung, H.W. 1992. Use of physiologically based pharmacokinetic models to establish biological exposure indexes. *Am Ind Hyg Assoc J* 53:369-374.
- Leung, H.W., and Paustenbach, D.J. 1990. Cancer risk assessment for dioxane based upon a physiologically-based pharmacokinetic approach. *Toxicol Lett* 51:147-162.
- Leung, H.W., and Paustenbach, D.J. 1995. Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances. *Toxicol Lett* 79:55-65.
- Leung, H.W., Ku, R.H., Paustenbach, D.J., and Andersen, M.E. 1988. A physiologically-based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. *Toxicol Lett* 42:15-28.
- Leung, H.W., Paustenbach, D.J., Murray, F.J., and Andersen, M.E. 1990. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. *Toxicol Appl Pharmacol* 103:399-410.
- Leung, H.W., Poland, A., Paustenbach, D.J., Murray, F.J., and Andersen, M.E. 1990. Pharmacokinetics of [125I]-2-iodo-3,7,8-trichlorodibenzodioxin in mice: analysis with a physiological modeling approach. *Toxicol Appl Pharmacol* 103:411-419.

- Lilly, P.D., Thornton-Manning, J.R., Gargas, M.L., Clewell, H.J., and Andersen, M.E. 1998. Kinetic characteristics of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. *Arch Toxicol* 72:609-621.
- Lindstedt, S.L., 1987. Allometry: body size constraints in animal design. In: *Pharmacokinetics in Risk Assessment: Drinking Water and Health*, Vol. 8. Washington, DC:National Academy Press, 65–79.
- Lipscomb, J.C., Meek, E., Krishnan, K., Kedderis, G.L., Clewell, H. and Haber, L.T. 2004. Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments. *Toxicol Mech Methods* 14:145-158.
- Louizou G.D., and Anders, M.W. 1993. Gas-uptake and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). *Drug Metab Dispos* 21:634-639.
- Louizou G.D., and Anders, M.W. 1995. Gas-uptake pharmacokinetics of 2-chloro-1,1,1,2-tetrafluoroethane (HCFC-124) in the rat, mouse, and hamster. *Drug Metab Dispos* 23:875-880.
- Louizou, G.D., Tran, C.L., and Anders, M.W. 1997. Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. *Xenobiotica* 27:87-99.
- Louizou, G.D., Urban, G., Dekant, W., and Anders, M.W. Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). *Drug Metab Dispos* 22:511-517.
- Luecke, R.H., Wosilait, W.D., Pearce, B.A., and Young, J.F. 1994. A physiologically based pharmacokinetic computer model for human pregnancy. *Teratology* 49:90-103.
- Lutz, R.J., Dedrick, R.L., Tuey, D., Sipes, I.G., Anderson, M.W., and Matthews, H.B. 1984. Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. *Drug Metab Dispos* 12(5):527-535.
- Mann, S., Droz, P.O., and Vahter, M. 1996. A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. *Toxicol Appl Pharmacol* 137:8-22.
- Mann, S., Droz, P.O., and Vahter, M. 1996. A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. *Toxicol Appl Pharmacol* 140:471-486.
- Mattie, D.R., Grabau, J.H., and McDougal, J.N. 1994. Significance of the dermal route of exposure to risk assessment. *Risk Anal* 14:277-284.
- Maxwell, D.M., Vlahacos, C.P., and Lenz, D.E. 1988. A pharmacodynamic model for soman in the rat. *Toxicology Lett* 43:175-188.
- McDougal, J.N., Jepson, G.W., Clewell, H.J., Gargas, M.L., and Andersen, M.E. 1990. Dermal absorption of organic chemical vapors in rats and humans. *Fundam Appl Toxicol* 14:299-308.
- McDougal, J.N., Jepson, G.W., Clewell, H.J., MacNaughton, M.G. and Andersen, M.E. 1986. A physiological pharmacokinetic model for dermal absorption of vapors in the rat. *Toxicol Appl Pharmacol* 85:286-294.
- McKone, T.E. 1993. Linking a PBPK model for chloroform with measured breath concentrations in showers: implications for dermal exposure models. *J Expo Anal Environ Epidemiol* 3:339-365.

McMahon, T.F., Medinsky, M.A., and Birnbaum, L.S. 1994. Age-related changes in benzene disposition in male C57BL/6N mice described by a physiologically based pharmacokinetic model. *Toxicol Lett* 74:241-253.

Medinsky, M.A. 1995. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances. *Toxicol Lett* 79:185-191.

Menzel, D.B. 1988. Planning and using PB-PK models: an integrated inhalation and distribution model for nickel. *Toxicol Lett* 43:1-3.

Mills, J.J., and Andersen, M.E. 1993. Dioxin hepatic carcinogenesis: biologically motivated modeling and risk assessment. *Toxicol Lett* 68:177-189.

Mumtaz M.M., Sipes I.G., Clewell H.J., and Yang R.S.H. 1993. Risk assessment of chemical mixtures: Biological and toxicologic issues. *Fundam Appl Toxicol* 21:258-269.

National Research Council, 1987. *Pharmacokinetics in Risk Assessment: Drinking Water and Health*, Vol 8. Washington DC:National Academy Press.

National Research Council. 1986. Dose-route extrapolations: Using inhalation toxicity data to set drinking water limits. In: *Drinking water and health*. Volume 6. National Academy Press, Washington D.C., p. 168-225.

Nichols, J.W., McKim, J.M., Andersen, M.E., Gargas, M.L., Clewell, H.J., and Erickson, R.J. 1990. A physiologically-based toxicokinetic model for the uptake and disposition of waterborne organic chemicals in fish. *Toxicol Appl Pharmacol* 106:433-447.

Nichols, J.W., McKim, J.M., Lien, G.J., Hoffman, A.D., Bertelsen, S.L., and Elonen, C.M. 1996. A physiologically based toxicokinetic model for dermal absorption of organic chemicals by fish. *Fundam Appl Toxicol* 31:229-242.

O'Flaherty, E.J., 1989. Interspecies conversion of kinetically equivalent doses. *Risk Anal* 9, 587-598.

O'Flaherty, E.J. 1991. Physiologically based models for bone seeking elements. I. Rat skeletal and bone growth. *Toxicol Appl Pharmacol* 111:299-312.

O'Flaherty, E.J. 1991. Physiologically based models for bone seeking elements. II. Kinetics of lead disposition in rats. *Toxicol Appl Pharmacol* 111:313-331.

O'Flaherty, E.J. 1991. Physiologically based models for bone seeking elements. III. Human skeletal and bone growth. *Toxicol Appl Pharmacol* 111:332-341.

O'Flaherty, E.J. 1993. Physiologically based models for bone seeking elements. IV. Kinetics of lead disposition in humans. *Toxicol Appl Pharmacol* 118:16-29.

O'Flaherty, E.J. 1995. PBPK modeling for metals. Examples with lead, uranium, and chromium. *Toxicol Lett* 82-83:367-372.

O'Flaherty, E.J. 1995. Physiologically based models for bone seeking elements. V. Lead absorption and disposition in childhood. *Toxicol Appl Pharmacol* 131:297-308.

O'Flaherty, E.J., Scott, W., Schreiner, C., and Beliles, R.P. 1992. A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid. *Toxicol Appl Pharmacol* 112:245-256.

OSHA. Occupational exposure to methylene chloride; final rule, 1997. *Fed Reg* 62:1493-1619.

Page, N.P., Singh, D.V., Farland, W., Goodman, J.I., Conolly, R.B., Andersen, M.E., Clewell, H.J., III, Frederick, C.B., Yamasaki, H., and Lucier, G. 1997. Implementation of EPA revised cancer risk assessment guidelines: Incorporation of mechanistic and pharmacokinetic data. *Fund Appl Toxicol* 37:16-36.

Pastino, G.M., Sultatos, L.G., and Flynn, E.J. 1996. Development and application of a physiologically based pharmacokinetic model for ethanol in the mouse. *Alcohol Alcohol* 31:365-374.

Paustenbach, D.J., Clewell, H.J., Gargas, M.L., and Andersen, M.E. 1988. A physiologically-based pharmacokinetic model for inhaled carbon tetrachloride. *Toxicol Appl Pharmacol* 96:191-211.

Pelekis, M., Poulin, P., and Krishnan, K. 1995. An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. *Toxicol Ind Health* 11:511-522.

Perbellini, L., Mozzo, P., Olivato, D., and Brugnone, F. 1990. "Dynamic" biological exposure indexes for n-hexane and 2,5-hexanedione, suggested by a physiologically based pharmacokinetic model. *Am Ind Hyg Assoc J* 51:356-362.

Pierce, C.H., Dills, R.L., Morgan, M.S., Nothstein, G.L., Shen, D.D., and Kalman, D.A. 1996. Interindividual differences in 2H8-toluene toxicokinetics assessed by semiempirical physiologically based model. *Toxicol Appl Pharmacol* 139:49-61.

Ploemen, J.P., Wormhoudt, L.W., Haenen, G.R., Oudshoorn, M.J., Commandeur, J.N., Vermeulen, N.P., de Waziers, I., Beaune, P.H., Watabe, T., and van Bladeren, P.J. 1997. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. *Toxicol Appl Pharmacol* 143:56-69.

Plowchalk, D.R., Andersen, M.E., and Bogdanffy, M.S. 1997. Physiologically based modeling of vinyl acetate uptake, metabolism, and intracellular pH changes in the rat nasal cavity. *Toxicol Appl Pharmacol* 142:386-400.

Plowchalk, D.R., Andersen, M.E., and DeBethizy, J.D. 1992. A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. *Toxicol Appl Pharmacol* 116:177-188.

Purcell, K.J., Cason, G.H., Gargas, M.L., Andersen, M.E., and Travis, C.C. 1990. In vivo metabolic interactions of benzene and toluene. *Toxicol Lett* 52:141-152.

Ramsey, J.C., and Andersen, M.E. 1984. A physiological model for the inhalation pharmacokinetics of inhaled styrene monomer in rats and humans. *Toxicol Appl Pharmacol* 73:159-175.

Rao, H.V., and Brown, D.R. 1993. A physiologically based pharmacokinetic assessment of tetrachloroethylene in groundwater for a bathing and showering determination. *Risk Anal* 13:37-49.

Rao, H.V., Beliles, R.P., Whitford, G.M., and Turner, C.H. 1995. A physiologically based pharmacokinetic model for fluoride uptake by bone. *Regul Toxicol Pharmacol* 22:30-42.

Reitz R.H., Mendrala, A.L., Park, C.N., Andersen, M.E., and Guengerich, F.P. 1988. Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: Implications for risk assessment. *Toxicol Lett* 43:97-116.

Reitz, R.H., Gargas, M.L., Andersen, M.E., Provan, W.F., and Green, T. 1996. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. *Toxicol Appl Pharmacol* 136:1-16.

Reitz, R.H., Gargas, M.L., Mendrala, A.L., and Schumann, A.M. 1996. In vivo and in vitro studies of perchloroethylene metabolism for physiologically based pharmacokinetic modeling in rats, mice, and humans. *Toxicol Appl Pharmacol* 136:289-306.

Reitz, R.H., McCroskey, P.S., Park, C.N., Andersen, M.E., and Gargas, M.L. 1990. Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane. *Toxicol Appl Pharmacol* 105:37-54.

Reitz, R.H., McDougal, J.N., Himmelstein, M.W., Nolan, R.J., and Schumann, A.M. 1988. Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. *Toxicol Appl Pharmacol* 95:185-199.

Reitz, R.H., Mendrala A.L., Corley, R.A., Quast, J.F., Gargas, M.L., Andersen, M.E., Staats, D.A., and Conolly, R.B. 1990. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. *Toxicol Appl Pharmacol* 105:443-459.

Reitz, R.H., Mendrala, A.L., and Guengerich, F.P. 1989. In vitro metabolism of methylene chloride in human and animal tissues: Use in physiologically-based pharmacokinetic models. *Toxicol Appl Pharmacol* 97:230-246.

Robinson, D.E., Balter, N.J., and Schwartz, S.L. 1992. A physiologically based pharmacokinetic model for nicotine and cotinine in man. *J Pharmacokinet Biopharm* 20(6):591-609.

Roth, R.A., and Vinegar, A. 1990. Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition. *Pharmacol Ther* 48:143-155.

Roy, A., Weisel, C.P., Liyo, P.J., and Georgopoulos, P.G. 1996. A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds. *Risk Anal* 16:147-160.

Sarangapani, R., Clewell, H.J., Cruzan, G., and Andersen, M.E. 2002. Comparing respiratory-tract and hepatic exposure-dose relationships for metabolized inhaled vapors: a pharmacokinetic analysis. *Inhal Toxicol* 14(8):835-854.

Sarangapani, R., Gentry, P.R., Covington, T.R., Teeguarden, J.G., and Clewell, H.J. 2003. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. *Inhal Toxicol* 15(10):987-1016.

Sarangapani, R., Teeguarden, J.G., Cruzan, G., Clewell, H.J., Andersen, M.E. 2002. Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. *Inhal Toxicol* 14(8):789-834.

- Sato, A., and Nakajima, T. 1979. A vial equilibration method to evaluate the drug metabolizing enzyme activity for volatile hydrocarbons. *Toxicol Appl Pharmacol* 47:41-46.
- Sato, A., and Nakajima, T. 1979. Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. *Br J Ind Med* 36:231-234.
- Sato, A., Endoh K, Kaneko, T., Johanson, G. 1991. A simulation study of physiological factors affecting pharmacokinetic behavior of organic solvent vapours. *Br J Ind Med* 48:342-347.
- Schreiber, J.S. 1993. Predicted infant exposure to tetrachloroethene in human breastmilk. *Risk Anal* 13:515-524.
- Semino, G., Lilly, P., and Andersen, M.E. 1997. A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. *Toxicology* 117:25-33.
- Sexton, K., Reiter, L.W., and Zenick, H. 1995. Research to strengthen the scientific basis for health risk assessment: a survey of the context and rationale for mechanistically based methods and models. *Toxicology* 102:3-20.
- Shelley, M.L., Andersen, M.E., and Fisher, J.W. 1988. An inhalation distribution model for the lactating mother and nursing child. *Toxicol Lett* 43:23-29.
- Shelley, M.L., Harris, R.L., and Boehlecke, B.A. 1996. A mathematical model of bronchial absorption of vapors in the human lung and its significance in pharmacokinetic modeling. *Environ Res* 5:221-253.
- Shipp, A.M., Gentry, P.R., Lawrence, G., VanLandingham, C., Covington, C., Clewell, H.J., Gribben, K., and Crump, K. 2000. Determination of a site-specific reference dose for methylmercury for fish-eating populations. *Toxicol Indust Health* 16(9-10):335-438.
- Sielken, Jr., R.L., Reitz, R.H., and Hays, S.M. 1996. Using PBPK modeling and comprehensive realism methodology for the quantitative cancer risk assessment of butadiene. *Toxicology* 113:231-237.
- Simmons, J.E. 1996. Application of physiologically based pharmacokinetic modelling to combination toxicology. *Food Chem Toxicol* 34:1067-1073.
- Smith, A.E., and Evans, J.S. 1995. Uncertainty in fitted estimates of apparent in vivo metabolic constants for chloroform. *Fundam Appl Toxicol* 25:29-44.
- Smith, A.E., Gray, G.M., and Evans, J.S. 1995. The ability of predicted internal dose measures to reconcile tumor bioassay data for chloroform. *Regul Toxicol Pharmacol* 21:339-351.
- Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., Mangelsdorf, I., Meek, E., Rice, J.M., Younes, M., 2001. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. *Regul. Toxicol. Pharmacol.* 34 (2), 146–152.
- Spear, R.C., and Bois, F.Y. 1994. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. *Environ Health Perspect* 102(Suppl 11):61-66.

Spear, R.C., Bois, F.Y., Woodruff, T., Auslander, D., Parker, J., and Selvin, S. 1991. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. *Risk Anal* 11:641-654.

Srinivasan, R.S., Bourne, D.W., and Putcha, L. 1994. Application of physiologically based pharmacokinetic models for assessing drug disposition in space. *J Clin Pharmacol* 34:692-698.

Staats, D.A., Fisher, J.W., and Connolly, R.B. 1991. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models: A two-compartment description. *Drug Metab Dispos* 19:144-148.

Sultatos, L.G., Kim, B., and Woods, L. 1990. Evaluation of estimations in vitro of tissue/blood distribution coefficients for organothiophosphate insecticides. *Toxicol Appl Pharmacol* 103:52-55.

Sweeney, L.M., Himmelstein, M.W., Schlosser, P.M., and Medinsky, M.A. 1996. Physiologically based pharmacokinetic modeling of blood and tissue epoxide measurements for butadiene. *Toxicology* 113:318-321.

Sweeney, L.M., Shuler, M.L., Quick, D.J., and Babish, J.G. 1996. A preliminary physiologically based pharmacokinetic model for naphthalene and naphthalene oxide in mice and rats. *Ann Biomed Eng* 24:305-320.

Tardif, R., Lapare, S., Charest-Tardif, G., Brodeur, J., and Krishnan, K. 1995. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. *Risk Anal* 15:335-342.

Tardiff, R., Lapare, S., Krishnan, K., and Brodeur, J. 1993. Physiologically based modeling of the toxicokinetic interaction between toluene and m-xylene in the rat. *Toxicol Appl Pharmacol* 120:266-273.

Teorell, T. 1937. Kinetics of distribution of substances administered to the body. I. The extravascular mode of administration. *Arch Int Pharmacodyn Ther* 57:205-225.

Teorell, T. 1937. Kinetics of distribution of substances administered to the body. I. The intravascular mode of administration. *Arch Int Pharmacodyn* 57:226-240.

Terry, K.K., Elswick, B.A., Welsch, F., and Conolly, R.B. 1995. Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse. *Toxicol Appl Pharmacol* 132:103-114.

Thakore, K.N., Gargas, M.L., Andersen M.E., and Mehendale, H.M. 1991. PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl<sub>3</sub> in rats pretreated with chlordecone, phenobarbital, or mirex. *Toxicol Appl Pharmacol* 109:514-528.

Thomas, R.S., Bigelow, P.L., Keefe, T.J., and Yang, R.S. 1996. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. *Am Ind Hyg Assoc J* 57:23-32.

Thomas, R.S., Lytle, W.E., Keefe, T.J., Constan, A.A., and Yang R.S. 1996. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method. *Fundam Appl Toxicol* 31:19-28.

Thomas, R.S., Yang, R.S., Morgan, D.G., Moorman, M.P., Kermani, H.R., Sloane, R.A., RW, O.C., Adkins, Jr., B., Gargas, M.L., and Andersen, M.E. 1996. PBPK modeling/Monte Carlo simulation of methylene chloride kinetic changes in mice in relation to age and acute, subchronic, and chronic inhalation exposure. *Environ Health Perspect* 104:858-865.

Thompson K.M., and Evans, J.S. 1993. Workers' breath as a source of perchloroethylene (Perc) in the home. *J Expo Anal Environ Epidemiol* 3:417-430.

Travis, C. and White, R. 1988. Interspecies scaling of toxicity data. *Risk Anal* 8:119-125.

Tuey, D.B., and Matthews, H.B. 1980. Distribution and excretion of 2,2',4,4',5,5'-hexabromobiphenyl in rats and man: Pharmacokinetic model predictions. *Toxicol Appl Pharmacol* 53:420-431.

U.S. Environmental Protection Agency (USEPA), 1987. Update To The Health Assessment Document and Addendum For Dichloromethane (Methylene Chloride): Pharmacokinetics, Mechanism Of Action, And Epidemiology. External Review Draft. EPA/600/8-87/030A. Office of Health and Environmental Assessment, USEPA, Washington, DC.

US Environmental Protection Agency. 1988. Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/004. Office of Health and Environmental Assessment, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 1992. EPA Request for Comments on Draft Report on Cross-Species Scaling Factor for Cancer Risk Assessment. *Fed Reg* 57:24152.

U.S. Environmental Protection Agency (USEPA), 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry EPA/600/8-90/066F. Office of Health and Environmental Assessment, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 1999. Toxicological Review of Ethylene Glycol Monobutyl Ether (EGBE) in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635-R00/004. National Center for Environmental Assessment, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 2000a. Toxicological Review of Vinyl Chloride in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635-R00/004. National Center for Environmental Assessment, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 2001b. Toxicological Review of Chloroform in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635-R01/001. National Center for Environmental Assessment, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 2002c. Perchlorate Environmental Contamination: Toxicological Review and Risk Characterization. External Review Draft. NCEA-1-0503. Office of Research and Development, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 2002d. Toxicological Review of Boron and Compounds in Support of Summary Information on the Integrated Risk Information System (IRIS). External Review Draft. National Center for Environmental Assessment, USEPA, Washington, DC.

U.S. Environmental Protection Agency (USEPA), 2003a. Draft Final Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001A. Risk Assessment Forum, USEPA, Washington, DC.

Vinegar, A., and Jepson, G.W. 1996. Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling. *Risk Anal* 16:571-579.

Vinegar, A., Auten, K.L., Seckel, C.S., Reed, Y.M., and Conolly, R.B. 1990. Physiologically based pharmacokinetic model of the metabolism of trichloroethylene by an isolated ventilated perfused lung. *Inhal Toxicol* 2:285-294.

Vinegar, A., Seckel, C.S., Pollard, D.L., Kinkead, E.R., Conolly, R.B., and Andersen, M.E. 1992. Polychlorotrifluoroethylene (PCTFE) oligomer pharmacokinetics in Fischer 344 rats: Development of a physiologically based model. *Fundam Appl Toxicol* 18:504-514.

Vinegar, A., Williams, R.J., Fisher, J.W., and McDougal, J.N. 1994. Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: a physiologically based pharmacokinetic model in the male Fischer 344 rat. *Toxicol Appl Pharmacol* 129:103-113.

Vinegar, A., Winsett, D.W., Andersen, M.E., and Conolly, R.B. 1990. Use of a physiologically based pharmacokinetic model and computer simulation for retrospective assessment of exposure to volatile toxicants. *Inhal Toxicol* 2:119-128.

Voisin, E.M., Ruthsatz, M., Collins, J.M., and Hoyle, P.C. 1990. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. *Regul Toxicol Pharmacol* 12:107-116.

Waller, C.L., Evans, M.V., and McKinney, J.D. 1996. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. *Drug Metab Dispos* 24:203-210.

Ward, R.C., Travis, C.C., Hetrick, D.M., Andersen, M.E., and Gargas M.L. 1988. Pharmacokinetics of tetrachloroethylene. *Toxicol Appl Pharmacol* 93:108-117.

Watanabe, K.H., and Bois, F.Y. 1996. Interspecies extrapolation of physiological pharmacokinetic parameter distributions. *Risk Anal* 16:741-754.

Weisel, C., Yu, R., Roy, A., and Georgopoulos, P. 1996. Biomarkers of environmental benzene exposure. *Environ Health Perspect* 104(Suppl 6):1141-1146.

Welsch, F., Blumenthal, G.M., and Conolly, R.B. 1995. Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. *Toxicol Lett* 82-83:539-547.

White, K.K., Conolly, R.B., Elswick, B.A., and Welsch, F. 1992. Refinement of a physiologically-based description of 2-methoxyethanol (2-ME) disposition in the pregnant mouse. *Teratology* 45:456-457.

Williams, R.J., Vinegar, A., McDougal, J.N., Jarabek, A.M., and Fisher, J.W. 1996. Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling. *Fundam Appl Toxicol*. 30:55-66.

Woodruff, T.J., Bois, F.Y., Auslander, D., and Spear, R.C. 1992. Structure and parameterization of pharmacokinetic models: their impact on model predictions. *Risk Anal* 12:189-201.

Yang, R.S., el-Masri, H.A., Thomas, R.S., and Constan, A.A. 1995. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. *Toxicol Lett* 82-83:497-504.

Yang, R.S., el-Masri, H.A., Thomas, R.S., Constan, A.A., and Tessari J.D. 1995. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. *Toxicol Lett* 79:193-200.

Young JF, Schwetz BA, Willhite CC, Kacew S, 1996. Symposium on pharmacokinetics/ pharmacodynamics in the developing system and impact on risk assessment: executive summary. *J Toxicol Environ Health* 49:339–355.